Search results
BioNTech SE (NASDAQ:BNTX) Receives $111.70 Average Target Price from Analysts
ETF DAILY NEWS· 21 hours agoShares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been given an average rating of “Hold” by the ten ratings firms that are currently covering the firm, MarketBeat.com ...
FDA vaccine advisers vote unanimously in favor of updated Covid-19 shot for fall
CNN.com· 3 days agoThe US Food and Drug Administration’s committee of independent advisers voted unanimously Wednesday...
Updated Covid-19 Vaccine Targeting JN.1 Recommended By FDA Panel
Forbes· 4 days agoThe Vaccines and Related Biological Products Advisory Committee of the FDA evaluated the...
Genmab and BioNTech report data from Phase II GCT1046-04 trial for mNSCLC
Clinical Trials Arena via Yahoo Finance· 6 days agoGenmab and BioNTech announced the initial data from the phase II GCT1046-04 trial, which evaluated...
What To Know About Personalized mRNA Cancer Vaccines After Promising Trials From Moderna And Merck
Forbes· 5 days agoCancer vaccines are finally showing promise as Moderna and Merck touted promising data on an...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 1 day agoBiotech stock hit a two-year high in February, but have trended sideways in the months since despite...
COVID vaccine makers ready updated shots for fall immunization drive (NYSE:PFE)
Seeking Alpha· 3 days agoPfizer (PFE), BioNTech (BNTX), Moderna (MRNA) and Novavax (NVAX) reaffirm commitment to provide...
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
Benzinga via AOL· 1 day agoOn Friday, Moderna Inc. (NASDAQ:MRNA) announced that it has submitted an FDA application for review...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 1 day agoSales also tumbled 20% to $14.88 billion, but topped forecasts for $13.87 billion. As expected,...
COVID shots should target variants with JN.1 lineage in 2024-25 campaign, US FDA advisers say By...
Investing.com· 3 days agoCOVID shots should target variants with JN.1 lineage in 2024-25 campaign, US FDA advisers say